Pembrolizumab in HER2-Positive Gastric Cancer

被引：3

作者：

Janjigian, Yelena Y. ^{[1
]}

Kawazoe, Akihito ^{[2
]}

Bai, Yuxian ^{[3
]}

Xu, Jianming ^{[4
]}

Lonardi, Sara ^{[5
]}

Metges, Jean Phillipe ^{[6
]}

Yanez, Patricio ^{[7
]}

Wyrwicz, Lucjan S. ^{[8
]}

Shen, Lin ^{[9
]}

Ostapenko, Yuriy ^{[10
]}

Bilici, Mehmet ^{[11
]}

Chung, Hyun Cheol ^{[12
]}

Shitara, Kohei

Qin, Shukui ^{[13
]}

Van Cutsem, Eric ^{[14
]}

Tabernero, Josep ^{[15
]}

Luo, Suxia ^{[16
]}

Mahave, Mauricio ^{[17
]}

Tang, Yong ^{[18
]}

Lowery, Maeve ^{[19
]}

Monteiro, Maria M. F. ^{[20
]}

Xu, Linzhi ^{[21
]}

Shih, Chie-Schin ^{[21
]}

Sharan, Kanu P. ^{[21
]}

Bhagia, Pooja ^{[21
]}

Rha, Sun Young ^{[12
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10029 USA

[2] Natl Canc Hosp East, Kashiwa, Japan

[3] Harbin Med Univ Canc Hosp, Harbin, Peoples R China

[4] Fifth Med Ctr Peoples Liberat Army, Beijing, Peoples R China

[5] Ist Oncol Veneto, Padua, Italy

[6] Univ Hosp Brest, Brest, France

[7] James Lind Canc Res Ctr, Temuco, Chile

[8] Maria Sklodowska Curie Natl Canc Res Inst, Warsaw, Poland

[9] Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China

[10] Natl Canc Inst, Kiev, Ukraine

[11] Ataturk Univ, Erzurum, Turkiye

[12] Yonsei Canc Ctr, Seoul, South Korea

[13] Canc Ctr Peoples Liberat Army, Nanjing, Peoples R China

[14] Univ Hosp Gasthuisberg, Leuven, Belgium

[15] Vall dHebron Univ Hosp, Inst Oncol, Barcelona, Spain

[16] Henan Canc Hosp, Zhengzhou, Peoples R China

[17] Fdn Arturo Lopez Perez, Santiago, Chile

[18] Xinjiang Med Univ, Canc Hosp, Urumqi, Peoples R China

[19] Trinity St Jamess Canc Inst, Dublin, Ireland

[20] Inst Canc Ceara, Fortaleza, CE, Brazil

[21] Merck, Rahway, NJ USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2024年

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1056/NEJMc2408121

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pembrolizumab in HER2-Positive Gastric Cancer The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy alone.

引用

页数：3

共 50 条

[21] Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer
Yoshioka, Takahiro
Shien, Kazuhiko
Namba, Kei
Torigoe, Hidejiro
Sato, Hiroki
Tomida, Shuta
Yamamoto, Hiromasa
Asano, Hiroaki
Soh, Junichi
Tsukuda, Kazunori
Nagasaka, Takeshi
Fujiwara, Toshiyoshi
Toyooka, Shinichi
CANCER SCIENCE, 2018, 109 (04) : 1166 - 1176
[22] Recent Progress in Treatment for HER2-Positive Advanced Gastric Cancer
Kawakami, Takeshi
Yamazaki, Kentaro
CANCERS, 2024, 16 (09)
[23] Clinicopathological features and endoscopic findings of HER2-positive gastric cancer
Oono, Yasuhiro
Kuwata, Takeshi
Takashima, Kenji
Yoda, Yusuke
Ikematsu, Hiroaki
Shitara, Kohei
Kinoshita, Takahiro
Yano, Tomonori
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2018, 32 (09): : 3964 - 3971
[24] HER2-positive gastric cancer identified by serum HER2: A case report
Saito, Mayuko
Kawakami, Yujiro
Yamashita, Kentaro
Nasuno, Hiroshi
Ishimine, Yu
Fukuda, Koichiro
Isshiki, Hiroyuki
Suzuki, Ryo
Arimura, Yoshiaki
Shinomura, Yasuhisa
ONCOLOGY LETTERS, 2016, 11 (06) : 3575 - 3578
[25] Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer
Yoshioka, Takahiro
Shien, Kazuhiko
Takahashi, Yuta
Kurihara, Eisuke
Namba, Kei
Ogoshi, Yusuke
Torigoe, Hidejiro
Sato, Hiroki
Yamamoto, Hiromasa
Soh, Junichi
Fujiwara, Toshiyoshi
Toyooka, Shinichi
CANCER RESEARCH, 2018, 78 (13)
[26] Clinicopathological features and endoscopic findings of HER2-positive gastric cancer
Yasuhiro Oono
Takeshi Kuwata
Kenji Takashima
Yusuke Yoda
Hiroaki Ikematsu
Kohei Shitara
Takahiro Kinoshita
Tomonori Yano
Surgical Endoscopy, 2018, 32 : 3964 - 3971
[27] Resistance mechanisms to HER2-targeting treatment in HER2-positive gastric cancer
Kang, Kyo Hwa
Nam, Ah-Rong
Park, Ji Eun
Bang, Ju-Hee
Ling, Jin
Jin, Mei Hua
Kim, Tae Yong
Han, Sae-Won
Song, Sang-Hyun
Im, Seock-Ah
Kim, Tae-You
Oh, Do-Youn
Bang, Yung-Jue
CANCER RESEARCH, 2015, 75
[28] Herceptin in metastatic HER2-positive gastric cancer - GEJ approved
Jelitto, H. -U.
VISZERALMEDIZIN, 2010, 26 (02): : 141 - 141
[29] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Shitara, Kohei
Bang, Yung-Jue
Iwasa, Satoru
Sugimoto, Naotoshi
Ryu, Min-Hee
Sakai, Daisuke
Chung, Hyun-Cheol
Kawakami, Hisato
Yabusaki, Hiroshi
Lee, Jeeyun
Saito, Kaku
Kawaguchi, Yoshinori
Kamio, Takahiro
Kojima, Akihito
Sugihara, Masahiro
Yamaguchi, Kensei
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25) : 2419 - 2430
[30] Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
Kotani, Daisuke
Shitara, Kohei
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13

← 1 2 3 4 5 →